U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT06857227) titled 'A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis' on Feb. 26.
Brief Summary: This study is a randomized controlled phase I clinical study with safety, efficacy, and pharmacokinetic/pharmacodynamic characteristics in patients with rheumatoid arthritis.
Study Start Date: March, 2025
Study Type: INTERVENTIONAL
Condition:
Rheumatoid Arthritis
Intervention:
DRUG: GNC-038
Administration by intravenous infusion. Once a week (IV, QW), twice in total.
DRUG: Placebo
The control group will be set up in phase Ib, and an appropriate dose will be selected based on phase Ia data.
Recruitment Stat...